Here’s Why Vertex Pharmaceuticals Stock (VRTX) Is Up 10% Today

FomoAnxiety · 2026-03-10T16:46:02+00:00

Vertex Pharmaceuticals' stock rose 10% after its kidney drug succeeded in a Phase 3 trial, demonstrating a 52% improvement in patient outcomes. This success is vital for diversifying beyond cystic fibrosis treatments, with potential revenues exceeding $10 billion. Analysts rate VRTX as a Strong Buy.

FomoAnxiety

2026-03-10 16:46:02

Abstract generation in progress

Vertex Pharmaceuticals’ VRTX +9.81% ▲ stock is up 10% on March 10 after the biotechnology company said that its experimental drug for a rare kidney disease succeeded in a Phase 3 clinical trial.

Claim 70% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

Analysts say the success of the new kidney drug is critically important to helping Vertex Pharmaceuticals
diversify beyond its main drugs that are used to treat the disease cystic fibrosis. The Boston-based company said its kidney drug improved outcomes for patients 52% of the time in a late-stage clinical trial.

That result passed the bar that analysts had set for Vertex’s kidney medication. Analysts say the trial marks an important first step in unlocking a new franchise in kidney disease treatments for Vertex Pharmaceuticals. The company is currently developing two treatments for kidney disease. Cantor Fitzgerald forecasts that the treatments could generate more than $10 billion in revenue a year for Vertex.

Vertex’s Current Sales

If estimates are accurate, Vertex’s new kidney drugs could eventually rival the company’s cystic fibrosis medication franchise, which brings in annual sales of more than $11 billion. The company has also expanded into blood disorders with the approval of its gene-editing treatment Casgevy and acute pain with its drug Journavx.

However, no new drugs have been a runaway success. Vertex transformed the treatment for cystic fibrosis with a suite of drugs for the inherited lung disorder, but the company has faced questions from pharmaceutical analysts about whether it can replicate that success among other medical conditions.

Is VRTX Stock a Buy?

Vertex stock has a consensus Strong Buy rating among 25 Wall Street analysts. That rating is based on 21 Buy and four Hold recommendations issued in the last three months. The average VRTX price target of $558.32 implies 10.56% upside from current levels.

Disclaimer & DisclosureReport an Issue

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes